-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although next-generation sequencing (NGS) of tumor tissue is the best method for whole-genome analysis, it is a challenge to obtain metastatic sites for tissue biopsy in castration-resistant prostate cancer (CRPC)
.
In addition, analyzing only one area of tumor tissue may not capture tumor heterogeneity within an individual
Cell-free DNA (cfDNA) testing is becoming an important tool to promote precise cancer treatment
.
cfDNA can be obtained only through blood draw, simple operation, little harm to patients, and can be repeated; circulating free tumor DNA (ctDNA) can capture the real-time gene profile of the tumor, including its heterogeneity
Precise
This study aims to identify the genomic profile of CRPC patients, including low-frequency variants in ctDNA, and to evaluate the clinical significance of detecting variants with a variant allele frequency (VAF) of less than 1%
.
This is a prospective multicenter cohort study that recruited CRPC patients who are suitable for treatment with abiraterone or enzalutamide
.
The researchers performed targeted sequencing on the cfDNA and paired white blood cell DNA of the test patients before treatment, and screened ctDNA variants with VAF ≥ 0.
Progression-free survival and overall survival when using different ctDNA tests to predict
Progression-free survival and overall survival when using different ctDNA tests to predictA total of 100 patients were recruited (median follow-up was 10.
7 months)
.
Even in samples with a ctDNA score of less than 2%, the researchers detected harmful ATM, BRCA2, and TP53 variants
Even in samples with a ctDNA score of less than 2%, the researchers detected harmful ATM, BRCA2, and TP53 variants
Detecting low-frequency ctDNA variants with VAF<1% is very important for identifying genomic changes with clinical information in patients with castration-resistant prostate cancer.
Original source:
Kei Mizuno, et al.
Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer in this message
